Jacob Zalaznick
Bristol-Myers Squibb (Germany)(DE)Bristol-Myers Squibb (United States)(US)Bristol-Myers Squibb (Sweden)(SE)
Publications by Year
Research Areas
Pancreatic function and diabetes, Cancer Immunotherapy and Biomarkers, Diabetes Treatment and Management, Receptor Mechanisms and Signaling, Biochemical and Molecular Research
Most-Cited Works
- → Discovery of 5-Chloro-4-((1-(5-chloropyrimidin-2-yl)piperidin-4-yl)oxy)-1-(2-fluoro-4-(methylsulfonyl)phenyl)pyridin-2(1H)-one (BMS-903452), an Antidiabetic Clinical Candidate Targeting GPR119(2014)45 cited
- → Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1H-pyrazol-1-yl)methyl)phosphonate (BMS-820132)(2022)9 cited
- → Immunoaffinity microflow liquid chromatography/tandem mass spectrometry for the quantitation of PD1 and PD‐L1 in human tumor tissues(2020)6 cited
- → A Peptide Immunoaffinity LC–MS/MS Strategy for Quantifying the GPCR Protein, S1PR1 in Human Colon Biopsies(2020)5 cited
- → Author response for "Immunoaffinity Micro‐Flow Liquid Chromatography/Tandem Mass Spectrometry for the Quantitation of PD1 and PD‐L1 in Human Tumor Tissues"(2020)
- → Discovery of liver-selective glucokinase activators comprising N-(4-alkylthiazol-2-yl)benzamides and N-(3-alkyl-1,2,4-thiadiazol-5-yl)benzamides for the treatment of metabolic disorders(2025)